171 related articles for article (PubMed ID: 15555549)
1. Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice.
Matsushita T; Hayashi H; Kunishima S; Hayashi M; Ikejiri M; Takeshita K; Yuzawa Y; Adachi T; Hirashima K; Sone M; Yamamoto K; Takagi A; Katsumi A; Kawai K; Nezu T; Takahashi M; Nakashima T; Naoe T; Kojima T; Saito H
Biochem Biophys Res Commun; 2004 Dec; 325(4):1163-71. PubMed ID: 15555549
[TBL] [Abstract][Full Text] [Related]
2. Absence of hearing loss in a mouse model for DFNA17 and MYH9-related disease: the use of public gene-targeted ES cell resources.
Parker LL; Gao J; Zuo J
Brain Res; 2006 May; 1091(1):235-42. PubMed ID: 16630581
[TBL] [Abstract][Full Text] [Related]
3. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
[TBL] [Abstract][Full Text] [Related]
4. [May-Hegglin anomaly--from genome research to clinical laboratory].
Kunishima S
Rinsho Byori; 2003 Sep; 51(9):898-904. PubMed ID: 14560660
[TBL] [Abstract][Full Text] [Related]
5. Detection of unique neutrophil non-muscle myosin heavy chain-A localization by immunofluorescence analysis in MYH9 disorder presented with macrothrombocytopenia without leukocyte inclusions and deafness.
Kunishima S; Matsushita T; Shiratsuchi M; Ikuta T; Nishimura J; Hamaguchi M; Naoe T; Saito H
Eur J Haematol; 2005 Jan; 74(1):1-5. PubMed ID: 15613099
[TBL] [Abstract][Full Text] [Related]
6. Analysis of clinical manifestations, mutant gene and encoded protein in two Chinese MYH9-related disease families.
Yi Y; Sen Zhang G; Xu M; San Ling Z; Ru Shao X; Zeng Li J; Ma J
Clin Chim Acta; 2006 Nov; 373(1-2):49-54. PubMed ID: 16806139
[TBL] [Abstract][Full Text] [Related]
7. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
Kunishima S
Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
[TBL] [Abstract][Full Text] [Related]
8. MYH9-related platelet disorders.
Althaus K; Greinacher A
Semin Thromb Hemost; 2009 Mar; 35(2):189-203. PubMed ID: 19408192
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of MYH9 mRNA at leukocyte inclusion bodies in MYH9 disorders.
Kunishima S; Hirano K; Hamaguchi M; Saito H
Eur J Haematol; 2008 Oct; 81(4):325-6. PubMed ID: 18616507
[No Abstract] [Full Text] [Related]
10. Expression of non-muscle type myosin heavy polypeptide 9 (MYH9) in mammalian cells.
Takubo T; Wakui S; Daigo K; Kurokata K; Ohashi T; Katayama K; Hino M
Eur J Histochem; 2003; 47(4):345-52. PubMed ID: 14706930
[TBL] [Abstract][Full Text] [Related]
11. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations.
Kunishima S; Yoshinari M; Nishio H; Ida K; Miura T; Matsushita T; Hamaguchi M; Saito H
Eur J Haematol; 2007 Mar; 78(3):220-6. PubMed ID: 17241369
[TBL] [Abstract][Full Text] [Related]
12. Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome).
Selleng K; Lubenow LE; Greinacher A; Warkentin TE
Eur J Haematol; 2007 Sep; 79(3):263-8. PubMed ID: 17655694
[TBL] [Abstract][Full Text] [Related]
13. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions.
Kunishima S; Matsushita T; Kojima T; Amemiya N; Choi YM; Hosaka N; Inoue M; Jung Y; Mamiya S; Matsumoto K; Miyajima Y; Zhang G; Ruan C; Saito K; Song KS; Yoon HJ; Kamiya T; Saito H
J Hum Genet; 2001; 46(12):722-9. PubMed ID: 11776386
[TBL] [Abstract][Full Text] [Related]
14. Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.
Sun XH; Wang ZY; Yang HY; Cao LJ; Su J; Yu ZQ; Bai X; Ruan CG
Acta Haematol; 2013; 129(2):106-13. PubMed ID: 23207509
[TBL] [Abstract][Full Text] [Related]
15. MYH9-siRNA and MYH9 mutant alleles: expression in cultured cell lines and their effects upon cell structure and function.
Li Y; Friedmann DR; Mhatre AN; Lalwani AK
Cell Motil Cytoskeleton; 2008 May; 65(5):393-405. PubMed ID: 18330899
[TBL] [Abstract][Full Text] [Related]
16. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations.
Kunishima S; Matsushita T; Kojima T; Sako M; Kimura F; Jo EK; Inoue C; Kamiya T; Saito H
Lab Invest; 2003 Jan; 83(1):115-22. PubMed ID: 12533692
[TBL] [Abstract][Full Text] [Related]
17. Identification of the first in cis mutations in MYH9 disorder.
Miyajima Y; Kunishima S
Eur J Haematol; 2009 Apr; 82(4):288-91. PubMed ID: 19191864
[TBL] [Abstract][Full Text] [Related]
18. [Case of an hemodialysis patient with MYH9 disorders].
Ishida R; Kusaba T; Kirita Y; Matsuoka E; Nakayama M; Uchiyama H; Kajita Y
Nihon Jinzo Gakkai Shi; 2011; 53(2):195-9. PubMed ID: 21516706
[TBL] [Abstract][Full Text] [Related]
19. MYH9 related platelet disorders - often unknown and misdiagnosed.
Althaus K; Najm J; Greinacher A
Klin Padiatr; 2011 May; 223(3):120-5. PubMed ID: 21567368
[TBL] [Abstract][Full Text] [Related]
20. First description of somatic mosaicism in MYH9 disorders.
Kunishima S; Matsushita T; Yoshihara T; Nakase Y; Yokoi K; Hamaguchi M; Saito H
Br J Haematol; 2005 Feb; 128(3):360-5. PubMed ID: 15667538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
